You are here

Generic Aclovate Gains Approval

HAWTHORNE, N.Y.--(BUSINESS WIRE)--July 30, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Alclometasone Dipropionate Ointment, USP 0.05% ("alclometasone ointment").

Taro's alclometasone ointment is bioequivalent to GlaxoSmithKline's Aclovate ointment, a low to medium potency topical corticosteroid product. Alclometasone ointment, a prescription product, is used for the treatment of inflammatory skin diseases. U.S. sales of Aclovate(R) ointment were approximately $2.5 million in 2003, according to industry sources.

Source: Taro Pharmaceuticals

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications